‘Strategic’ development of precision cancer medicine in the United States

The availability of advanced omics technologies has largely driven development of precision cancer medicine in the United States, but integration in routine cancer care has been challenging. Here, we consider some parameters that would enable a more coordinated, integrated, efficient, and equitable...

Descripción completa

Detalles Bibliográficos
Autor principal: Schilsky, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253098/
https://www.ncbi.nlm.nih.gov/pubmed/34053185
http://dx.doi.org/10.1002/1878-0261.13023
Descripción
Sumario:The availability of advanced omics technologies has largely driven development of precision cancer medicine in the United States, but integration in routine cancer care has been challenging. Here, we consider some parameters that would enable a more coordinated, integrated, efficient, and equitable implementation of precision cancer medicine.[Image: see text]

Ejemplares similares